Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - XG SCIENCES INCs109458_ex32-1.htm
EX-31.1 - EXHIBIT 31.1 - XG SCIENCES INCs109458_ex31-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K/A

Amendment No. 1

 

Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934:
  For the fiscal year ended:   December 31,  2016
   
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934:
  For the transition period from: 

 

    XG SCIENCES, INC.    
    (Exact name of registrant as
specified in its charter)
   

 

Michigan   333-209131   20-4998896
(State or other jurisdiction of
incorporation or organization)
  (Commission File No.)   (I.R.S. Employer Identification
No.)

 

3101 Grand Oak Drive

Lansing, MI 48911 

(Address of principal executive offices) (zip code)

 

(517) 703-1110

(Issuer Telephone number)

 

Securities registered under Section 12(b) of the Act:   None.

 

Securities registered under Section 12(g) of the Act:   None.

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   Yes ☐   No  ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.    Yes ☐   No  ☒

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ☒   No  ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes ☐   No  ☒

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.   Yes  ☒   No  ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):   Yes ☐   No  ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, and accelerated filer, a non-accelerated filer, or a smaller reporting company, and whether the registrant is an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 

 

Large accelerated filer   ☐ Accelerated filer   ☐
Non-accelerated filer (Do not check if a smaller reporting company)   ☐ Smaller reporting company   ☒

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

As of June 30, 2016, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately $7,462,352, based on the price at which the common equity was last sold (i.e., $8.00 per share).

 

The number of shares outstanding of the registrant’s Common Stock, no par value per share, as of March 31, 2017 was 1,981,650.

 

 

 

 

 Explanatory Note

 

This Amendment No. 1 on Form 10-K/A (this “Amendment No. 1”) amends XG Sciences, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2016, originally filed with the Securities and Exchange Commission on March 31, 2017 (the “Original Filing”) for the purpose of correcting a scrivener’s error with respect to the signature page thereto. Amendment No. 1 speaks as of the date of the Original filing, does not reflect events that may have occurred after the date of the Original 10-K and does not modify or update in any way the disclosures made in the Original 10-K, except as described above. Amendment No. 1 should be read in conjunction with the Original 10-K and with the Company's subsequent filings with the SEC. As required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by our principal executive officer and principal financial officer are being filed as exhibits to this Amendment No. 1.

 

 

 

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

EXHIBIT
NUMBER
  DESCRIPTION   LOCATION
3.1   First Amendment to the Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock, dated November 20, 2013   Incorporated by reference to the Company’s Form S-1 filed with the SEC on January 26, 2016
         
3.2   Second Restated Bylaws dated March 3, 2017   Incorporated by reference to the Company’s Form S-1 filed with the SEC on January 26, 2016
         
3.3   Certificate of Designations of Series B Convertible Preferred Stock, effective September 9, 2015   Incorporated by reference to the Company’s Form S-1 filed with the SEC on January 26, 2016
         
3.4   First Amended and Restated Certificate of Designations of Series B Convertible Preferred Stock, effective August 18, 2016   Incorporated by reference to the Company’s Form S-1, as amended, filed with the SEC on January 10, 2017
         
4.1   Warrant to Purchase 5,000 Shares of Common Stock, dated October 8, 2012, issued by XG Sciences, Inc. to Michael R. Knox, together with Notice and Certificate of Adjustment to Warrant, dated August 21, 2013   Incorporated by reference to the Company’s Form S-1 filed with the SEC on January 26, 2016
         
4.2   Warrant to Purchase 833,333 Shares of Series A Convertible Preferred Stock, dated January 15, 2014, issued by XG Sciences, Inc. to Aspen Advanced Opportunity Fund, LP   Incorporated by reference to the Company’s Form S-1 filed with the SEC on January 26, 2016
         
4.3   Warrant to Purchase 83,333 Shares of Series A Convertible Preferred Stock, dated January 15, 2014, issued by XG Sciences, Inc. to XGS II, LLC   Incorporated by reference to the Company’s Form S-1 filed with the SEC on January 26, 2016
         
4.4   Warrant to Purchase 100,000 Shares of Series A Convertible Preferred Stock, dated January 15, 2014, issued by XG Sciences, Inc. to SVIC No. 15 New Technology Business Investment L.L.P.   Incorporated by reference to the Company’s Form S-1 filed with the SEC on January 26, 2016
         
10.1   Form of Warrant for Series B Unit Offering   Incorporated by reference to the Company’s Form S-1 filed with the SEC on January 26, 2016
         
10.2   Form of December Note for December Placement   Incorporated by reference to the Company’s Form S-1 filed with the SEC on January 26, 2016
         
10.3   Form of December Warrant for December Placement   Incorporated by reference to the Company’s Form S-1 filed with the SEC on January 26, 2016

 

1

 

 

10.4   Form of Subscription Agreement for December Placement   Incorporated by reference to the Company’s Form S-1 filed with the SEC on January 26, 2016
         
10.5   Form of Subscription Agreement for Primary Offering   Incorporated by reference to the Company’s Form S-1, as amended, filed with the SEC on April 5, 2016
         
10.6   First Amendment to Shareholder Agreement, dated February 26, 2016   Incorporated by reference to the Company’s Form S-1, as amended, filed with the SEC on March 1, 2016
         
10.7   Draw Loan Note and Agreement, dated as of December 7, 2016, by and between the Company and Dow   Incorporated by reference to the Company’s current report on Form 8-K filed with the SEC on December 9, 2016
         
14   Code of Ethics   Incorporated by reference to the Company’s Form S-1 filed with the SEC on January 26, 2016
         
21   Subsidiary   Incorporated by reference to the Company’s Form S-1, as amended, filed with the SEC on March 1, 2016
         
31.1   Certifications of the Chief Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   Filed herewith
         
32.1   Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of the Sarbanes-Oxley Act Of 2002*   Furnished herewith
         
101. INS   XBRL Instance Document   Incorporated by reference to the Company’s annual report on Form 10-K filed with the SEC on March 31, 2017
         
101. CAL   XBRL Taxonomy Extension Calculation Link base Document   Incorporated by reference to the Company’s annual report on Form 10-K filed with the SEC on March 31, 2017
         
101. DEF   XBRL Taxonomy Extension Definition Link base Document   Incorporated by reference to the Company’s annual report on Form 10-K filed with the SEC on March 31, 2017
         
101. LAB   XBRL Taxonomy Label Link base Document   Incorporated by reference to the Company’s annual report on Form 10-K filed with the SEC on March 31, 2017
         
101. PRE   XBRL Extension Presentation Link base Document   Incorporated by reference to the Company’s annual report on Form 10-K filed with the SEC on March 31, 2017
         
101. SCH   XBRL Taxonomy Extension Scheme Document   Incorporated by reference to the Company’s annual report on Form 10-K filed with the SEC on March 31, 2017

 

2

 

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

XG SCIENCES, INC.

 

Dated: March 26, 2018 By:   /s/ Philip L. Rose
  Name:   Philip L. Rose
  Title:   Chief Executive Officer, President,
Treasurer, Principal Executive Officer and
Principal Financial Officer
       

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

/s/ Philip L. Rose   Chief Executive Officer, President, Treasurer, Director,   March 26, 2018
Philip L. Rose   Principal Executive Officer and Principal Financial Officer    
         
/s/ Corinne Lyon   Controller and Principal Accounting Officer   March 26, 2018
Corinne Lyon        
         
/s/ Arnold A. Allemang   Chairman of the Board   March 26, 2018
Arnold A. Allemang        
         
/s/ Steven C. Jones   Director   March 26, 2018
Steven C. Jones        
         
/s/ Dave Pendell   Director   March 26, 2018
Dave Pendell        

 

SUPPLEMENTAL INFORMATION TO BE FURNISHED WITH REPORTS FILED PURSUANT TO SECTION 15(D) OF THE ACT BY REGISTRANTS WHICH HAVE NOT REGISTERED SECURITIES PURSUANT TO SECTION 12 OF THE ACT.

 

No such annual report, proxy statement, form of proxy or other soliciting material has been sent to its Noteholders. The registrant will not be sending an annual report or proxy material to its Noteholders subsequent to the filing of this form.

 

3